Attrition in the therapeutic pipeline can typically result from a lack of translational efficacy between the pre-clinical phase and the clinic. Organoids offer much promise in drug screening and ...
Protocol complexity, sensitivity to errors, and substantial training requirements make cell culture passaging difficult.
Attrition in the therapeutic pipeline is often linked to the gap in translational efficacy between the pre-clinical phase and clinical outcomes. Organoids offer strong potential for improving disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results